Skip to content

Optimization of diagnosis and treatment plan for idiopathic membranous nephropathy in the integrative medicine

Optimization of diagnosis and treatment plan for idiopathic membranous nephropathy in the integrative medicine

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006126
Enrollment
Unknown
Registered
2022-06-14
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Membranous Nephropathy

Interventions

blood stasis:Qilong Tongshen Granules
humid stasis type:Fenqinghuazhuo capsules

Sponsors

Shanxi Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ( 1 ) Patients with idiopathic membranous nephropathy ( IMN ) nephrotic syndrome confirmed by renal biopsy and clinical examination were pathologically divided into stages I to II ; ( 2 ) Age in 18-75 years old, gender, ethnic limit ; ( 3 ) signing informed consent ; ( 4 ) TCM syndromes are qi deficiency and blood stasis or damp heat and blood stasis ; ( 4 ) 24-hour urinary protein excretion > 3.5g / 24h ( 5 ) Serum creatinine = 133umol / L or endogenous creatinine clearance rate 60ml / min / 1.73m2 was included in the study.

Exclusion criteria

Exclusion criteria: ( 1 ) Pregnancy or lactation patients ; ( 2 ) Complicated with severe primary diseases such as decompensated cirrhosis, active malignant tumor or hematopoietic system ; ( 3 ) Those with acute myocardial infarction, cerebral infarction or cerebral hemorrhage in the first three months were included ; ( 4 ) Severe arrhythmia, severe heart failure, NYHA class III or above ; ( 5 ) Patients with severe infectious diseases when included ; ( 6 ) Patients with clear thrombosis were included ; ( 7 ) During the treatment period, the patients with natural loss or loss of follow-up, poor compliance and discontinued or not taking medicine, there are serious adverse events, serious other patients with onset or deterioration.

Design outcomes

Primary

MeasureTime frame
plasma albumin;24 hours urinary protein excretion;

Secondary

MeasureTime frame
blood total cholesterol;serum creatinine;blood urea nitrogen;triglyceride;low density lipoprotein;urine routine;high density lipoprotein;

Countries

China

Contacts

Public ContactWang shi rong
wangshirongrong@126.com13934661226

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026